乌龙制药（UroGen Pharma，股票代码：URGN）今日盘前大跌5.50%，主要原因是公司公布的第二季度财报显示净亏损超出分析师预期。
根据财报，乌龙制药第二季度净亏损为4994万美元，远高于分析师预期的4000万美元。虽然公司的JELMYTO产品收入同比增长11%，达到2422万美元，超出了分析师2310万美元的预期，但这一亮点似乎被巨额亏损所掩盖。公司第二季度运营费用高达6211万美元，其中研发费用为1890万美元，这些因素共同导致了较大的亏损。
尽管如此，乌龙制药也传来了一些积极消息。美国食品药品监督管理局（FDA）批准了公司的新药ZUSDURI，这被认为是公司产品组合的重要里程碑。公司预计ZUSDURI拥有超过50亿美元的市场机会。此外，乌龙制药预计2025年全年JELMYTO收入将达到9400万至9800万美元。然而，这些利好消息似乎未能抵消投资者对公司短期财务表现的担忧，导致股价出现大幅下跌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.